CS Diagnostics licenses and commercializes CS Group products, holds exclusive U.S. rights to CS Protect-Hydrogel, MEDUSA long-acting surface disinfectant.
CS Diagnostics Corp. retracts its 2022–2025 financial statements after identifying a $499.4 million intangible asset misclassified in a September 2023 deal. The Board concludes the asset was improperly recognized under fair-value accounting instead of ASC 805-50 rules for common control transactions. The error stems from a transaction involving intangible assets, now deemed non-compliant with accounting standards.
CS Diagnostics Corp. (CSDX) finalizes the conversion of preferred shares to common stock for its affiliates, CS Interpharm and CS Diagnostics Pharma. The move aligns the company’s subsidiaries under consolidated financial reporting, reinforcing operational integration within the CS Group. CSDX specializes in advanced medical and wellness products, serving markets in the U.S. and internationally.
CS Diagnostics Corp. initiates a **Regulation D, Rule 506(c) investment offering** to support its development of advanced medical technologies aimed at improving patient safety and health outcomes. The company, listed on the OTCQB under the ticker **CSDX**, leverages this funding to accelerate its mission in medical diagnostics. The offering represents a key step in scaling operations and expanding its technological capabilities.
CS Diagnostics Corp. resumes full-scale operations and achieves regulatory milestones for its flagship products, **CS-Protect Hydrogel** and **MEDUSA**, while securing a strategic capital raise. The company targets expanded market share in the U.S. with enhanced financial transparency and operational scaling.
CS Diagnostics Corp has filed a patent application for its CS-Protect Hydrogel in the US. The company partners with Paul & Albrecht Patent Lawyers to navigate the intellectual property process.
CS Diagnostics Corp hires Lachman Consultants to support FDA approval of its **CS-Protect Hydrogel**, a medical-grade hydrogel product. The move aims to accelerate regulatory review for the diagnostic or wound-care application. The company has not disclosed specific use cases or timelines for approval.